Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Eagle Pharmaceuticals, Inc is a drug manufacturers—specialty & generic business based in the US. Eagle Pharmaceuticals shares (EGRX) are listed on the NASDAQ and all prices are listed in US Dollars. Eagle Pharmaceuticals employs 108 staff and has a trailing 12-month revenue of around USD$177.4 million.
|52-week range||USD$33.8 - USD$64.94|
|50-day moving average||USD$41.2466|
|200-day moving average||USD$46.6341|
|Wall St. target price||USD$49.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.177|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Eagle Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eagle Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Eagle Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 258x. In other words, Eagle Pharmaceuticals shares trade at around 258x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Eagle Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.91. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eagle Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Eagle Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$11.7 million.
The EBITDA is a measure of a Eagle Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$177.4 million|
|Operating margin TTM||4.6%|
|Gross profit TTM||USD$135 million|
|Return on assets TTM||1.97%|
|Return on equity TTM||-2.53%|
|Market capitalisation||USD$596.8 million|
TTM: trailing 12 months
There are currently 2.3 million Eagle Pharmaceuticals shares held short by investors – that's known as Eagle Pharmaceuticals's "short interest". This figure is 27.4% up from 1.8 million last month.
There are a few different ways that this level of interest in shorting Eagle Pharmaceuticals shares can be evaluated.
Eagle Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Eagle Pharmaceuticals shares currently shorted divided by the average quantity of Eagle Pharmaceuticals shares traded daily (recently around 220674.29951691). Eagle Pharmaceuticals's SIR currently stands at 10.35. In other words for every 100,000 Eagle Pharmaceuticals shares traded daily on the market, roughly 10350 shares are currently held short.
However Eagle Pharmaceuticals's short interest can also be evaluated against the total number of Eagle Pharmaceuticals shares, or, against the total number of tradable Eagle Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eagle Pharmaceuticals's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 Eagle Pharmaceuticals shares in existence, roughly 180 shares are currently held short) or 0.2873% of the tradable shares (for every 100,000 tradable Eagle Pharmaceuticals shares, roughly 287 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Eagle Pharmaceuticals.
Find out more about how you can short Eagle Pharmaceuticals stock.
We're not expecting Eagle Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Eagle Pharmaceuticals's shares have ranged in value from as little as $33.8 up to $64.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eagle Pharmaceuticals's is 0.6922. This would suggest that Eagle Pharmaceuticals's shares are less volatile than average (for this exchange).
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.